Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Tisdall

Interventional Pain Medicine San Antonio, TX Medical Doctor

NPI 1124153754 CMS profile 232743

1919 Rogers Rd, Suite 204, San Antonio, TX 78251

Open in the dashboard

General payments

$30,449

263 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Tisdall of San Antonio, TX is reported in the CMS Open Payments database as having received $30,449 across 263 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,605 28
2024 General $7,981 38
2023 General $703 42
2022 General $639 32
2021 General $6,091 44
2020 General $7,409 21
2019 General $1,019 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Tisdall
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to William Tisdall were reported at $6,605. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year William Tisdall Interventional Pain Medicine median Middle half National median
2019 $1,019 $684 $216–$2,079 $163
2020 $7,409 $382 $122–$1,109 $114
2021 $6,091 $552 $167–$1,554 $132
2022 $639 $605 $187–$1,924 $149
2023 $703 $671 $195–$1,915 $160
2024 $7,981 $684 $206–$1,837 $164
2025 $6,605 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $28,866 192 payments
  2. Abbott Laboratories $447 16 payments
  3. Medtronic, Inc. $281 13 payments
  4. SI-BONE, Inc. $202 4 payments
  5. Daiichi Sankyo Inc. $124 10 payments
  6. Nevro Corp. $95 5 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $85 5 payments
  8. Medtronic USA, Inc. $64 2 payments
  9. Nalu Medical, Inc. $51 3 payments
  10. Collegium Pharmaceutical, Inc. $50 2 payments
  11. Other $184 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $13,075 6 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,850 5 payments
  3. Food and Beverage $5,190 246 payments
  4. Travel and Lodging $1,334 6 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $6,144 64 payments
  2. SPECTRA WAVEWRITER $5,602 22 payments
  3. WAVEWRITER ALPHA $4,300 7 payments
  4. GENERAL PAIN MANAGEMENT $1,758 26 payments
  5. General - Therapies General - Therapies_NMD $938 3 payments
  6. GENERAL - PAIN MANAGEMENT Pain Management $824 4 payments
  7. General - Therapies Therapies $800 1 payment
  8. General - Pain Management General - Pain Management_NMD $733 23 payments
  9. Neuromodulation Dspsbls and Accs $248 8 payments
  10. IFUSE IMPLANT $152 2 payments
  11. Other $1,337 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

5,452

Median for Interventional Pain Management: 1,220

Drug cost

$196,338

Median for Interventional Pain Management: $39,344

Branded share of claims

82.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 4,077 $123,822
Percocet Oxycodone Hcl/Acetaminophen Brand 11 $35,691
Naloxone Hcl Generic 183 $11,776
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 271 $6,767
Oxycodone Hcl Generic 322 $5,872
Morphine Sulfate Er Morphine Sulfate Brand 160 $4,943
Hydromorphone Hcl Generic 155 $2,094
Lidocaine Generic 12 $1,372
Pregabalin Generic 27 $938
Morphine Sulfate Generic 42 $922

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$118,464

Of which drugs: $263

Medicare patients

356

Average age 72

Services billed

2,630

208 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Depression 30%
Chronic kidney disease 29%
Ischemic heart disease 26%
Osteoporosis 18%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 71 370 $108
Injection, midazolam hydrochloride, per 1 mg J2250 Office 96 576 $62
Injection, ketorolac tromethamine, per 15 mg J1885 Office 50 114 $56
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 84 321 $29

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record